Catalyst Pharmaceutical
CPRX
Market cap $2.62B

21.52 USD

+0.50

2.38%

Updated Jul 30, 10:50 AM EDT

1 day

2.38%

5 days

0.00%

1 month

-0.83%

3 months

-11.40%

6 months

-7.20%

Year to date

0.00%

1 year

25.33%

5 years

357.87%

10 years

340.08%

About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Employees: 167

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

353% more call options, than puts

Call options by funds: $2.48M | Put options by funds: $547K

118% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 33

100% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 6 (+3) [Q1 2025]

17% more capital invested

Capital invested by funds: $2.04B [Q4 2024] → $2.38B (+$348M) [Q1 2025]

9% more funds holding

Funds holding: 334 [Q4 2024] → 365 (+31) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 121

0.96% less ownership

Funds ownership: 81.77% [Q4 2024] → 80.82% (-0.96%) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CPRX.

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about CPRX published over the past 30 days

Zacks Investment Research

CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?

CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

Zacks Investment Research

Rising Cash Flows Make These 4 Stocks Worth Choosing Now

CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.

Rising Cash Flows Make These 4 Stocks Worth Choosing Now

Zacks Investment Research

Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns

Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.

Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Zacks Investment Research

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Zacks Investment Research

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Zacks Investment Research

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Zacks Investment Research

CPRX or STVN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

CPRX or STVN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

See News Rankings

Charts implemented using Lightweight Charts™